Compare FAMI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAMI | CTXR |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 16.8M |
| IPO Year | 2017 | 2010 |
| Metric | FAMI | CTXR |
|---|---|---|
| Price | $1.25 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 10.5K | ★ 625.2K |
| Earning Date | 08-04-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.63 |
| 52 Week High | $2.22 | $2.38 |
| Indicator | FAMI | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 41.06 |
| Support Level | $1.23 | $0.70 |
| Resistance Level | $1.39 | $0.99 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 8.22 | 6.57 |
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe and the Middle East under the Forasen and Farmmi brands.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.